Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19.


Journal

Angiology
ISSN: 1940-1574
Titre abrégé: Angiology
Pays: United States
ID NLM: 0203706

Informations de publication

Date de publication:
02 2021
Historique:
pubmed: 1 9 2020
medline: 22 1 2021
entrez: 1 9 2020
Statut: ppublish

Résumé

With the global expansion of coronavirus disease 2019 (COVID-19) and the declaration of its outbreak as a Public Health Emergency of International Concern by the World Health Organization, there is an urgent need for vaccines and medicines to prevent and treat COVID-19. The responsible pathogen for the disease is the newly severe acute respiratory syndrome coronavirus (SARS-CoV) 2 belonging to the same family of viruses SARS-CoV and Middle East respiratory syndrome coronavirus that originally are zoonotic and have been associated with severe illness during the outbreaks in 2003 and 2012, respectively. The virulence of coronavirus strains is mainly associated with variations in surface proteins mediating cellular entry of the virus, which can help in finding effective therapeutic targets. In this review, we seek evidence showing the role of coronavirus spike protein (S-protein) and its potential cellular receptor, angiotensin-converting enzyme 2 (ACE2), during infection of coronaviruses, including the newly SARS-CoV-2 and its similar strain SARS-CoV. This review also discusses the therapeutic effect of inhibiting the renin-angiotensin system cascade, a target of ACE2, in patients having coronavirus with cardiovascular disease.

Identifiants

pubmed: 32864982
doi: 10.1177/0003319720952284
doi:

Substances chimiques

Spike Glycoprotein, Coronavirus 0
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

122-130

Auteurs

Amir Abbas Momtazi-Borojeni (AA)

Halal Research Center of IRI, FDA, Tehran, Iran.

Maciej Banach (M)

Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Lodz, Poland.
37800Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland.

Željko Reiner (Ž)

Department of Internal Medicine, 37631University Hospital Center Zagreb, Croatia.

Matteo Pirro (M)

Unit of Internal Medicine, Angiology and Arteriosclerosis Diseases, Department of Medicine, University of Perugia, Italy.

Vanessa Bianconi (V)

Unit of Internal Medicine, Angiology and Arteriosclerosis Diseases, Department of Medicine, University of Perugia, Italy.

Khalid Al-Rasadi (K)

Medical Research Center, Sultan Qaboos University, Muscat, Oman.

Amirhossein Sahebkar (A)

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Neurogenic Inflammation Research Center, 37552Mashhad University of Medical Sciences, Mashhad, Iran.
School of Pharmacy, 37552Mashhad University of Medical Sciences, Mashhad, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH